+491.7%
ASTS vs MRNA
+179.0%
+312.7%
-78.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -12.3% | -3.6% | -8.7% | -12.0% |
| 7D | -22.5% | -20.0% | -2.6% | -20.7% |
| 30D | -29.7% | -1.3% | -28.5% | -29.5% |
| 3M | -59.7% | +240.0% | -299.7% | -67.3% |
| 6M | -65.8% | +339.0% | -404.8% | -74.8% |
| YTD | -60.6% | +630.0% | -690.6% | -75.5% |
| 1Y | -53.5% | +769.1% | -822.5% | -72.4% |
| All | +491.7% | +179.0% | +312.7% | +252.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling